Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas

NCT00374699 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T-Cell Lymphomas
Non-Hodgkin Lymphoma

Interventions

DRUG: Velcade

Sponsor

Samsung Medical Center

Collaborators

[object Object]